Ann: AGM Presentation, page-70

First 70 Last

Share
Profile

Follow
BT6487

2,014 Posts.

645

05/01/24

12:18

Post #: 71740928
Share

Originally posted by vrs37: ↑

dr manhattan is right, this is a biased echo chamber. With lot of self-righteous waffle.
by “misrepresentation of facts” what you really mean is misrepresentation of your version of the facts singhu .
again you’re in denial or can’t read so let’s dig into the diabetes kidney disease a bit more and cut through your fantasy
# “Dimerix drug fails to best placebo in diabetes kidney disease study” as reported S&P global market intelligence on 15/9/2020. Clear and 100% correct . If u don’t like “flopped” I can use failed or flunked. Nobody except gullible investors falls for the questionable attempt to distract from the overall negative result by presenting it as a triumph via a post hoc p- hacked subgroup analysis. (Look up p- hacking if you don’t know what it is). It says something that 3 years after communicating results to market this study is not discoverable on any reputable scientific abstract or published paper. The results page in clinical trials .gov under this study remains blank. Why might that be Singhu?
# ANN 7/6/22: “new” diabetes trial announced. Protocol “currently being finalised”, study “expected to commence in Q4 2022”
# 4c 27/7/22: same thing, study to “commence “late 2022”
# 4c 27/10/22: plan to “initiate study in late 2022”,
#AGM 29/11/22- slide 13, “pre IND planned with FDA in Q1 2023”.
# whole of 2023…. Nothing. This “new” trial has vanished from face of earth. Nothing traceable on any trial platform either.
Come clean Singhu- there’s no diabetes trial is there. It doesn’t exist, never has. You really think it ever will ? Do you think the pre-IND mtg ever happened? If it did, what feedback did they get from fda that prevented an announcement? Care to venture Singhu? Based on these ANNs through 2022 about the trial is it possible some people got breadcrumbed and bought in in 2022 thinking this diabetes trial was really near term.

COPD? Good luck with that one. As I posted before, the Dmx asset is reported to be il8 blocker. Human (as opposed to mouse) copd trials already show il8 inhibition to have weak efficacy or toxic . That’s why some big Pharma companies have abandoned those assets. A 10 minute search will show this. Still optimistic?

Expand

The people that invested here long ago mainly invested for FSGS. Nina has made it clear DKD was on the backburner as FSGS is the priority., as orphan drug designation equals faster route to market

Last edited by BT6487: 05/01/24

DXB Price at posting: 24.5¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply